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resourceMuhammad Zeeshan Afzal and Melanie Gartzontact person and
emailJennifer Strande, jstrande@mcw.eduate archived/stock
dateSeptember 2015rigin Human urine-derived cells
pe of resource Induced pluripotent stem cells (iPSC) generated from
patient with homozygous PAI-1 mutation
b-type Human induced pluripotent stem cells
ey transcription
factorsOct3/4, Sox2, Klf4, and cMycuthentication Identity and purity of the cell line conﬁrmed (Fig. 2)
nk to related
literature
formation in public
databases
thics Patient informed consent obtained and procedures were
approved by the Institutional Review Boards (IRBs) at the
Medical College of Wisconsin (Milwaukee, WI) and St.
Vincent's Health (Indianapolis, IN).. This is an open access article underResource details
Plasminogen Activator Inhibitor-1 (PAI-1) is the physiological inhibi-
tor of plasminogen activation and has a canonical role inﬁbrinolysis. PAI-
1 also contributes to a diverse range of biological effects like physiological
aging (Yamamoto et al., 2014, Eren et al., 2014b), replicative senescence
(Elzi et al., 2012, Eren et al., 2014b,Wan et al., 2014), proteolysis (Eren et
al., 2014a), extracellularmatrix interaction (Flevaris andVaughan, 2016),
adhesion (Viswanathan et al., 2006),migration (Kozlova et al., 2015) and
other signaling functions. Complete deﬁciency of PAI-1 in humans is rare
but the obvious clinical manifestation is abnormal bleeding after trauma
(Fay et al., 1992, 1997, Heiman et al., 2014). The effects of PAI-1 deﬁcien-
cy in its other biological roles have been more elusive to study in the
human system. The ability to derive human induced pluripotent stem
cells (iPSCs) from patients with a PAI-1 null mutation would allow the
production of large numbers of target cells for further investigation. We
generated human iPSC clones fromurine cells of subjectswith a homozy-
gous dinucleotide (TA) insertion within exon 4 of the PAI-1 gene (Fay et
al., 1992, 1997). iPSC clones were established under feeder-free culture
conditions using the CytoTune® iPS Reprogramming Kit (Life Technolo-
gies, Carlsbad, CA)which employs thenon-integrating Sendai virus to de-
liver reprogramming factors, OCT3/4, SOX2, KLF4 and cMYC (Takahashi
et al., 2007). Themorphologic iPAI-026-C-K iPSC clones displayed typical
pluripotent cellmorphology (Fig. 2A). The iPSC clones stainedpositive for
the pluripotencymarkers Oct3/4 and TRA-1-81 (Fig. 2B). The presence of
endogenous pluripotency markers OCT3/4 and SOX2, and the absence of
exogenous reprogramming transgenes KLF4, cMYC and SeV in later iPSC
passages were conﬁrmed by RT-PCR (Fig. 2C). Demonstration of three
germ layer differentiation capacity was conﬁrmed by immunoﬂuores-
cence analysis of SOX1, OTX2, BRY and GATA4 to identify ectoderm,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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bodies (Fig. 2D). The iPSC clone showed normal karyotype (46, XX)
(Fig. 2E) and the PAI-1 mutation was conﬁrmed by genomic sequencing
(Fig. 2F).Materials and methods
Urine sample collection and urine cell isolation
All procedures described were approved by the Institutional Review
Boards (IRBs) at theMedical College ofWisconsin (Milwaukee,WI) and
St. Vincent's Health (Indianapolis, IN). Subject enrollment and sample
collection occurred at a distant site. After informed consent was obtain-
ed, subjects were instructed on to collect a sterile mid-stream catch
urine sample in a sterile urine cup available commercially. The samples
were aseptically processed under a portable laminar ﬂow hood and
were transferred to sterile 50 mL centrifuge tubes and spun at 400 ×g
for 10 min. The urine supernatant was discarded after aspiration and
the remaining pellet with particulate portion was resuspended with
2 mL of collection/storage media (1 volume Keratinocyte Serum Free
(KSF) Medium, 1 volume Progenitor Cell Medium +1 volume FBS).
Samples were stored on ice for 24–48 h until transported back to the
laboratory where the urine cell isolation and culturing continued as de-
scribed byAfzal and Strande (2015). The cellswere expanded for amax-
imum of 5 passages when they were either directly reprogrammed or
banked in liquid nitrogen for future experiments.Non-integrative reprogramming of UCs into iPSCs
Urine cells grown to 80–90 percent conﬂuency were exposed to the
Sendai virus (SeV) vectors included in the CytoTune® iPS
Reprogramming Kit (Life Technologies, Carlsbad, CA) at a multiplicity
of infection of 1.5. After 24 h, themediawas replacedwith freshUPCme-
dium daily. Once iPSC-like clones with cobblestone morphology appear
on day 5 or 6 post SeV transduction, the reprogrammed UCs were disso-
ciated with trypsin-EDTA, resuspended in UPC medium (supplemented
with 5 μMY27632, RhOKinase inhibitor) and seeded onto freshmatrigel
(10 μg/cm2) coated 12 well plates in the ratio ranging from 1:5–1:10.
The next day, culture medium was replaced with TeSR-E8 supplement
(Stem Cell Technologies, Vancouver, BC Canada). The media wasSeV
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Fig. 1. Schematic representation of the protocol. (A) Urine derived cells are cultured and reprog
for reprogramming UCs.replaced daily until individual iPSC-like clones were large enough to
be selected for picking and expansion, usually by day 14 (Fig. 1A–B).Embryoid body formation and differentiation
Dissociated iPSC cloneswere suspended in embryoid body induction
(EB) Medium (KO-DMEM, 20% KSR, penicillin/streptomycin, Glutamax,
β-mercaptoethanol and non-essential amino acids) and transferred to 6
well suspension culture plates (CELLSTAR, Greiner Bio-One, Monroe,
NC) under hypoxic conditions. After 4–5 days, EBswere plated onto gel-
atin coated chamber slides and cultured under normoxic conditions in
differentiation medium (DMEM/F12 with 20% FBS, penicillin/strepto-
mycin, Glutamax, β-mercaptoethanol and non-essential amino acids)
for 6–7 days until conﬂuent.Immunoﬂuorescence staining
Cells grown on matrigel-coated chamber slides were ﬁxed with 4%
paraformaldehyde, permeabilized with PBS containing 0.1% Triton X-
100, and incubated with CAS-Block™ (Thermo Fischer Scientiﬁc Inc.,
Waltham, MA) for 30 min. Unconjugated primary antibodies to Oct3/4
(Santa Cruz Biotechnology, Dallas, Texas) and TRA-1-81 (Thermo Fi-
scher Scientiﬁc Inc.), or ﬂuorochrome conjugated antibodies to SOX1,
Otx-2, Brachyury, andGATA4 (Human Three Germ Layer 3-Color Immu-
nocytochemistry Kit, R&D Systems Inc., Minneapolis, MN) were incu-
bated overnight at 4 °C. When necessary, cells were incubated with
ﬂuorochrome conjugated secondary antibodies (Thermo Fischer Scien-
tiﬁc Inc.) for 4 h at room temperature under humid conditions. Cover-
slips were mounted with ﬂuorshield mounting medium containing
nuclear counterstain DAPI (Sigma Aldrich, St. Louis, MO). Cells were vi-
sualized with confocal imaging (Nikon A1-R confocal microscope;
Nikon Instruments Inc., Melville, NY).Reverse transcription polymerase chain reaction (RT-PCR)
Total RNA was extracted using the Qiagen RNeasy Mini Kit (Qiagen,
Valencia, CA) and complementary DNA (cDNA) was synthesized from
1 μg of total mRNA using iScript cDNA synthesis kit (BioRad Laborato-
ries, Hercules, CA). RT-PCR was performed with the primers listed in
Table 1. Ampliﬁcation followed an initial denaturation at 95 °C forsduction
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Fig. 2. Characterization of iPSCs and genotypic evaluation. (A) Phase contrast micrograph of the cultured iPSC clone, plated under feeder-free conditions on matrigel. Scale bar, 50 μm. (B)
Pluripotency of iPSCs conﬁrmed by immunostaining with Oct3/4 (Red) and TRA-1-81 (green) markers and counterstained nuclei with blue DAPI stain. Scale bar, 50 μm. (C) RT-PCR gene
expression analysis show upregulation of endogenous pluripotent genes (Oct3/4 and Sox2) and elimination of the non-integrating viral genome and exogenous genes (SeV, Klf4 and
cMyc). (D) Differentiation into three embryonic germ layers was conﬁrmed after processing iPSCs to form embryoid bodies (EBs) and allowing spontaneous in vitro differentiation.
Ectoderm, mesoderm and endoderm characterized by immunostaining with Otx 2 (Red)/SOX1 (Green), Brachyury (Red), and GATA4 (Green), respectively. Scale bar, 50 μm. (E)
Karyogram of iPSCs demonstrates normal ploidy of a female subject. (F) Electropherogram conﬁrms the dinucleotide (TA) mutation gene sequence on the exon 4 of PAI-1 gene in
homozygous iPSCs (iPAI-026-C-K).
659M.Z. Afzal et al. / Stem Cell Research 17 (2016) 657–6605 min, and 35 cycles of 95 °C for 30 s, 55 °C for 30 s, and 72 °C for 30 s,
and ﬁnal extension at 72 °C for 7 min.
Karyotype analysis
Chromosomes of at least 20 proliferating cells per linewere counted
and fully analyzed using G-banding by Wisconsin Diagnostic Services
(Milwaukee, WI).
Assessment of PAI-1 mutation
Genomic DNA from iPSCswas extracted using QIAampDNAMini Kit
(Qiagen) and a genomic 753 bp fragment ﬂanking the mutation sitewithin exon 4 of PAI-1 gene was PCR ampliﬁed. The PAI-1 primer set
used for the ampliﬁcation is listed in Table 1. PCR productswere puriﬁed
using QIAquick PCR puriﬁcation kit (Qiagen) and sent to Retrogen, Inc.
(San Diego, CA) for DNA sequencing.
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List of primer sequences used for RT-PCR or genotyping analysis.
SeV (Exogenous)
Forward GGATCACTAGGTGATATCGAGC
Reverse ACCAGACAAGAGTTTAAGAGATATGTATC
Klf4 (Exogenous) Forward TTCCTGCATGCCAGAGGAGCCC
Reverse AATGTATCGAAGGTGCTCAA
cMyc (Exogenous) Forward TAACTGACTAGCAGGCTTGTCG
Reverse TCCACATACAGTCCTGGATGAT
Oct3/4 (Endogenous) Forward CAGTGCCCGAAACCCACAC
Reverse GGAGACCCAGCAGCCTCAAA
Sox2 (Endogenous) Forward CAAGATGCACAACTCGGAGA
Reverse GTTCATGTGCGCGTAACTGT
GAPDH Forward GTGGACCTGACCTGCCGTCT
Reverse GGAGGAGTGGGTGTCGCTGT
PAI-1 (Exon-4) Forward CCTGACTGCAGCCCTTTGACATACA
Reverse ACATCTAGAGCATTCCCTGTGGTCTTCCTC
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